IRD — Opus Genetics Income Statement
0.000.00%
Last trade - 00:00- $117.90m
- $86.47m
- $10.99m
Annual income statement for Opus Genetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.589 | 39.9 | 19 | 11 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 16.3 | 23.3 | 21.6 | 29.6 | 73.1 |
| Operating Profit | -16.3 | -22.7 | 18.2 | -10.6 | -62.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -24.6 | -56.7 | 18.2 | -9.97 | -57.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -24.6 | -56.7 | 17.9 | -9.99 | -57.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -24.6 | -56.7 | 17.9 | -9.99 | -57.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -24.6 | -56.7 | 17.9 | -9.99 | -57.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.82 | -3.62 | 0.868 | -0.402 | -1 |